ECTRIMS

Tecfidera has been on the market for a few years to help treat relapsing remitting multiple sclerosis and through extended studies and watching the market positive results have been seen by patients using the oral treatment.

Even as more medications are developed for relapsing remitting multiple sclerosis patients those with the primary progressive form have been left waiting for news on their condition. According to recent studies the first step in that process may soon be coming to the market.

With doctors having to take on more administrative work in addition to their patient care duties finding systems that can help them accomplish their goals without adding more time consuming tasks can be crucial.

Newer medications for the treatment of multiple sclerosis have been developed in recent years but for some patients interferon remains the starting point for pharmaceutical options.

Just as overactive bladder issues and constipation are an issue for patients with multiple sclerosis, mirabegron is a popular medication in the general population for managing these issues. At the NYU Langone Medical Center Comprehensive Care Center patients receive treatment from a wide variety of healthcare professionals in order to get the best results possible for their condition.

As patients with multiple sclerosis get older memory loss becomes a growing problem. Ways to slow that process including digital technology to help keep a patient's brain sharp.

Optic neuritis is linked to multiple sclerosis and a treatment to help patients with this condition continues to work its way through the research and approval process. Unlike other areas of multiple sclerosis treatment there is no singular way to measure or determine cognitive impairment in patients.

In 1992 the European Committee For Treatment And Research in Multiple Sclerosis met in Barcelona with 200 people in attendance. Twenty three years later the same conference was held in the same city with more than 9000 people in attendance and more than 1000 abstracts submitted.

While many areas of multiple sclerosis treatment have made progress in recent years working to help patients through issues with cognition is still an inexact science though work is being done to correct that.

The ECTRIMS conference may be based in Europe but as the conference has grown so has its global impact on multiple sclerosis treatment. With topics ranging from newly approved therapies to those in the pipeline to those not yet ready for testing there is lots to learn in the yearly event.

In the world of multiple sclerosis treatment the relapsing remitting form of the disease is well ahead of the primary progressive form.

A pair of phase III studies revealed positive efficacy and safety outcomes for ocrelizumab, and this could be a game-changer for patients with multiple sclerosis (MS).

Patients with multiple sclerosis (MS) commonly experience tremoring limbs, head pain, and blurred vision, among other symptoms. Fatigue is another commonly reported and has the power to alter a patient's quality of life (QoL). But by how much?

Results from clinical trials that included patients with relapsing-remitting multiple sclerosis (RRMS) do not appear to be consistent for patients with primary progressive multiple sclerosis (PPMS), according to Markus W. Koch, MD, from the University of Calgary in Alberta, Canada.

It's not uncommon for patients with multiple sclerosis (MS) to experience a reduction in brain volume. However, treatment with alemtuzumab can slow the process, according to a multi-continental team of investigators.

For patients with multiple sclerosis (MS), disturbances in the thermoregulation can result in episodic hypothermia. It's believed that this is caused by hypothalamic lesions from the disease, however, the specifics are not fully understood. M. Toledano and colleagues from the University of Utah set out to uncover more in a poster session that will be presented at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2015) in Barcelona, Spain.

Katarina Fink, an associate in the Department of Clinical Neuroscience at the Karolinska Institutet in Sweden, and colleagues analyzed the influence that multiple sclerosis (MS) has on a woman's fertility – an area that has remained unclear. The findings will be described in a poster session at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2015) in Barcelona, Spain.

MR-PET imaging can reveal inflammation and neurodegeneration in the brain, among other things, and a recent study showed that it can also help determine the progression of multiple sclerosis (MS).

With some patients being treated for multiple sclerosis with Aubagio for more than a decade questions have been raised about the safety of the treatment for such a long period of time. Further research has shown it to still be safe for the people who need it most.

It can be easy to look at the treatment of multiple sclerosis and stop at the physical symptoms of the disease. For patients living with the condition their daily lives are about more than the symptoms and making them work within their own individual challenges.

Magnetic resonance imaging (MRI) can be used to identify lesions in the central nervous system in patients with multiple sclerosis (MS), but not all patients with active disease have identifiable lesions, and researchers are mixed over the extent to which lesions can be used as a marker for MS disease activity.

Delayed-release dimethyl fumarate (DMF, also known as gastro-resistant DMF) is effective at lowering disease activity long-term in patients with relapsing-remitting multiple sclerosis (RRMS), according to Eva Havrdova, MD, of Charles University of Prague. The findings are set to be presented in a poster session at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2015) in Barcelona, Spain.

When it comes to treating and studying multiple sclerosis, the correlation between magnetic resonance imaging (MRI) lesions and actual disease activity has been widely disputed. A new analysis says that using MRI lesions as a proxy for disease activity is a sufficient approach when determining primary endpoints in clinical trials.

The results from an on-going phase 4 trial add to the growing evidence that teriflunomide is effective for relapsing-remitting multiple sclerosis, according to Patricia K. Coyle, MD, of Stony Brook University in New York.

Better understanding the relationship between inflammation and biomarkers could help improve treatments for those with multiple sclerosis.

Delayed-release dimethyl fumarate (DMF) proved to be safe and effective in two phase 3 studies, DEFINE and CONFIRM, for patients with relapsing-remitting multiple sclerosis (RRMS). Gavin Giovannoni, MBBCh, PhD, FRCP, FRCPath, of the Queen Mary University of London and colleagues took a more detailed look to verify the data.

Alemtuzumab is an effective strategy to prevent relapses and other disease activity associated with multiple sclerosis (MS), according to Heinz Wiendl, MD, a professor at the University of Münster. The research will be explained in a poster session at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2015) in Barcelona, Spain.

Race and vitamin D levels may play a crucial role in the risk of multiple sclerosis (MS), according to Annette M. Langer-Gould, MD, PhD, of Kaiser Permanente in Pasadena, California. The findings are set to be presented in a poster session at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2015) in Barcelona, Spain.

Paul Wicks, PhD, comments on physicians' acceptance of technological evolution in data collection at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston.

Paul Wicks, PhD, discusses the surge in Internet-savvy patients at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston.